Updates on HIV Pre-exposure Prophylaxis in Latin America: Available Drugs and Implementation Status
Infezioni in Medicina · 01.03.2025 · 33 (1)
DOI: 10.53854/liim-3301-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Infezioni in Medicina, online erschienen am 01.03.2025. Verfasst von Christian Gonzales-Gavancho und 12 weiteren Autor:innen. Beteiligte Einrichtung: Peruvian American Medical Society (PAMS), Albuquerque, NM 87111, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Latin America has reported a 9% increase in new HIV infections from 2010 to 2023. Pre-exposure prophylaxis (PrEP) is a crucial biomedical intervention for preventing HIV transmission. Currently, several antiretroviral drugs, in various forms of administration, have demonstrated high efficacy and effectiveness to protect against HIV. Among the oral drugs, we have emtricitabine/tenofovir and emtricitabine/tenofovir alafenamide, while alternative options include the dapivirine vaginal ring, injectable drugs such as Cabotegravir, and the most recently studied Lenacapavir. Despite their high efficacy and effectiveness, implementing PrEP in Latin America has been challenging throughout the region. Although some countries such as Brazil, Mexico, and Colombia have shown progress in increasing the number of users, there is a significant gap between these countries and others where PrEP access remains limited or non-existent. Barriers such as lack of awareness, inadequate funding, political instability, and outdated policies contribute to disparities in access, leaving many populations at high risk of HIV infection without this preventative measure. Innovative strategies need to be implemented to address and monitor policies that ensure access for all at-risk populations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Peruvian American Medical Society (PAMS), Albuquerque, NM 87111, USA.
- Asociacion Civil Impacta Salud y Educación, Lima 15063, Perú.
- Division of Infectious Diseases, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
- Grupo de Investigación Neurociencias, Metabolismo, Efectividad Clínica y Sanitaria (NEMECS), Universidad Científica del Sur, Lima 150142, Perú.
- Universidad Nacional de la Amazonia Peruana, Iquitos 16000, Perú.
- Universidad Nacional San Luis Gonzaga, Ica 11001, Perú.
Zitieren
APA
Gonzales-Gavancho, C., Araoz-Salinas, J. M., Ramon Tapia, R., Quispe-Vicuña, C., Reategui-Garcia, M. E., Rios-Garcia, W., Baltodano-Calle, M. J., Belanovic-Ramirez, I., Ortiz-Pardo, A. N., Ortiz-Saavedra, B., Campos, V. Y. M., Alave, J., & Gonzales-Zamora, J. A. (2025). Updates on HIV Pre-exposure Prophylaxis in Latin America: Available Drugs and Implementation Status. Infezioni in Medicina, 33(1). https://doi.org/10.53854/liim-3301-4
Vancouver
Gonzales-Gavancho C, Araoz-Salinas JM, Ramon Tapia R, Quispe-Vicuña C, Reategui-Garcia ME, Rios-Garcia W, et al. Updates on HIV Pre-exposure Prophylaxis in Latin America: Available Drugs and Implementation Status. Infezioni in Medicina. 2025;33(1). doi:10.53854/liim-3301-4
BibTeX
@article{GonzalesGavancho2025,
author = {Gonzales-Gavancho, Christian and Araoz-Salinas, Julieta M and Ramon Tapia, Ruth and Quispe-Vicuña, Carlos and Reategui-Garcia, Martin E and Rios-Garcia, Wagner and Baltodano-Calle, Maria Jose and Belanovic-Ramirez, Ivana and Ortiz-Pardo, Allison N and Ortiz-Saavedra, Brando and Campos, Victor Y M and Alave, Jorge and Gonzales-Zamora, Jose A},
title = {Updates on HIV Pre-exposure Prophylaxis in Latin America: Available Drugs and Implementation Status},
journal = {Infezioni in Medicina},
year = {2025},
volume = {33},
number = {1},
doi = {10.53854/liim-3301-4}
}
EUVIMED